Eli Lilly and Company announced new long-term data from its LUCENT-3 clinical study evaluating Omvoh (mirikizumab-mrkz) in patients with moderately to severely active ulcerative colitis. The results, which build upon previously disclosed findings, show that approximately 80% of Omvoh-treated patients who achieved clinical remission at one year maintained long-term, corticosteroid-free clinical and endoscopic remission over four years. Nearly all patients who achieved clinical remission at one year also showed improvements in bowel urgency, a common symptom in ulcerative colitis. The long-term safety profile remained consistent with previous data, with no new safety signals observed. These results have already been presented and further detail the sustained efficacy and safety of Omvoh in this patient population.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: DE91004) on October 07, 2025, and is solely responsible for the information contained therein.